Overview

Vevorisertib (ARQ 751) (4440-001) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations

Status:
Terminated

Trial end date:
2021-03-10

Target enrollment:

Participant gender:

Summary

An open-label, Phase 1b, study of vevorisertib as a single agent or in combination with other anti-cancer agents, in subjects with advanced solid tumors with PIK3CA / AKT / PTEN mutations.

Phase:

Phase 1

Details

Lead Sponsor:

ArQule
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)

Treatments:

Fulvestrant
Paclitaxel